Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GEHC
GEHC logo

GEHC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
75.180
Open
74.030
VWAP
74.40
Vol
2.25M
Mkt Cap
33.83B
Low
73.865
Amount
167.09M
EV/EBITDA(TTM)
11.56
Total Shares
456.29M
EV
39.61B
EV/OCF(TTM)
19.93
P/S(TTM)
1.65
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
Show More

Events Timeline

(ET)
2026-04-16
16:10:00
GE HealthCare Expands Collaboration with DeepHealth to Advance AI Mammography Tools
select
2026-04-09 (ET)
2026-04-09
09:10:00
GE HealthCare and Medtronic Launch Surgical Navigation System Integration
select
2026-03-26 (ET)
2026-03-26
08:40:00
GE HealthCare Joins COMPASS Consortium with €50.5 Million Budget
select
2026-03-25 (ET)
2026-03-25
09:10:00
GE HealthCare Showcases Cardiology Innovations at ACC.26
select

News

Newsfilter
7.5
04-16Newsfilter
Structural Shift in U.S. Heart Care Market
  • Market Growth Potential: The U.S. cardiovascular devices market is projected to grow from $22.08 billion in 2025 to $41.29 billion by 2032, reflecting a nearly 11.3% annual growth rate, indicating significant demand driven by an aging population.
  • AI Tool Adoption: Currently, 75% of U.S. health systems are rolling out AI-powered clinical tools, particularly in cardiac imaging and documentation, which will create asymmetric growth opportunities for companies in this sector.
  • New Partnership: VentriPoint Diagnostics has secured a new partnership with the Montecristo Group to deploy its AI cardiac imaging platform across Costa Rica, which is expected to enhance the efficiency and accuracy of cardiac disease screening in the region, further expanding market share.
  • Technological Advantage: VentriPoint's VMS+™ system converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRIs at a significantly lower cost, which is anticipated to drive the widespread adoption of cardiac diagnostics.
CNBC
7.5
04-07CNBC
Exxon Mobil Gains from Middle East War Impacting Helium Supply
  • Market Opportunity: The ongoing Middle East war has tightened global helium supply, with UBS analysts noting that Exxon Mobil stands to benefit as a net beneficiary of helium market conditions, particularly as Qatar's production is disrupted.
  • Production Capacity: Exxon's LaBarge facility in Wyoming is capable of producing approximately 1.4 billion cubic feet of Grade A helium annually, remaining unaffected by Middle Eastern events, and is expected to play a significant role in helium supply for the next eight decades.
  • Price Surge: Spot helium prices have soared to $1,000-$1,200 per thousand cubic feet due to the war, up from about $500 under older contracts, with UBS estimating that every $100 increase in prices could add $119 million to Exxon's EBITDA.
  • Investment Rating: UBS reiterated a buy rating for Exxon Mobil with a 12-month price target of $171, implying about 5% upside from Monday's close of $163.37, reflecting positive market sentiment regarding the company's growth prospects.
Yahoo Finance
6.5
04-03Yahoo Finance
Profitable Companies May Not Last
  • Caution on GE Healthcare: GE Healthcare's annual revenue growth of only 2.7% over the past two years significantly lags behind other healthcare firms, indicating core business struggles that may necessitate acquisitions for growth stimulation, with a current share price of $70.42 and a forward P/E of 14.2x.
  • Northern Trust's Slow Growth: Northern Trust has experienced muted annual revenue growth of 5.8% over the last five years, with its EPS growth of 9.3% falling short of peer averages, trading at $142.24 per share and a forward P/E of 13x, reflecting demand lagging behind financial performance.
  • Doximity's Strong Performance: Doximity boasts an impressive annual revenue growth of 29.3% over the past five years, showcasing market share gains, and its user-friendly software allows clients to quickly ramp up spending, with a current stock price of $22.94 and a forward price-to-sales ratio of 6.7x, indicating robust cash flow and investment flexibility.
  • High-Quality Stocks in Focus: While many profitable companies exist, not all are poised for sustained growth; analysis reveals that only a select few can maintain high-quality growth across various market conditions, prompting investors to focus on these potential winners.
NASDAQ.COM
8.0
04-01NASDAQ.COM
Analysis of GEHC Dividend Predictions and Stock Performance
  • Dividend Yield Analysis: GEHC's estimated annualized dividend yield stands at 0.20%, and while dividends are not always predictable, historical data can aid in assessing the likelihood of future dividend sustainability, impacting investor return expectations.
  • Price Volatility Range: The 52-week low for GEHC is $57.65 per share, with a high of $89.77, while the latest trade price is $71.45, indicating that the stock is within its volatility range, which may influence investor buying decisions.
  • ETF Holdings Overview: According to ETF Finder, GEHC comprises 10.07% of the AGF U.S. Market Neutral Anti-Beta Fund (BTAL), which is trading down approximately 1.3% on the day, reflecting overall market sentiment towards GEHC.
  • Intraday Trading Performance: In Wednesday trading, GEHC shares are up about 0.7%, indicating a short-term bullish sentiment in the market, which may attract more investor attention.
PRnewswire
7.5
03-27PRnewswire
Heart Disease Crisis Fuels AI Diagnostic Platforms
  • Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
  • Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
  • Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
  • Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
Newsfilter
7.5
03-27Newsfilter
Heart Disease Crisis Fuels AI Diagnostic Platforms
  • Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives each year, driving institutional capital towards scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
  • Growth in AI Medical Device Registrations: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second-largest category, providing a robust regulatory foundation that supports the rapid growth of companies in this sector.
  • Remote Healthcare Collaboration: VentriPoint Diagnostics has partnered with First Light Health to deliver AI-powered cardiac diagnostics to Indigenous and remote communities in Canada, utilizing the VMS+™ system to enhance accessibility and efficiency in healthcare delivery.
  • Technological Innovation and Market Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with MRI-level accuracy at a lower cost, positioning the company to expand into underserved global communities and address significant gaps in heart disease diagnosis.
Wall Street analysts forecast GEHC stock price to rise
13 Analyst Rating
Wall Street analysts forecast GEHC stock price to rise
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
80.00
Averages
92.25
High
105.00
Current: 0.000
sliders
Low
80.00
Averages
92.25
High
105.00
Piper Sandler
Overweight
downgrade
$96 -> $88
AI Analysis
2026-04-17
New
Reason
Piper Sandler
Price Target
$96 -> $88
AI Analysis
2026-04-17
New
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on GE HealthCare to $88 from $96 and keeps an Overweight rating on the shares. The firm is adding the recent acquisition of Intelerad into its model. This is inclusive of an additional $270M in annual revenue, $75M increase in annual adjusted EBIT, and EPS that is slightly dilutive in 2026 and accretive in 2027 and 2028.
Mizuho
Outperform
to
Outperform
downgrade
$95 -> $90
2026-04-13
Reason
Mizuho
Price Target
$95 -> $90
2026-04-13
downgrade
Outperform
to
Outperform
Reason
Mizuho lowered the firm's price target on GE HealthCare to $90 from $95 and keeps an Outperform rating on the shares. The firm lowered estimates and price targets for several names in its medical devices and diagnostics coverage ahead of Q1 earnings from the group.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GEHC
Unlock Now

Valuation Metrics

The current forward P/E ratio for GE Healthcare Technologies Inc (GEHC.O) is 14.49, compared to its 5-year average forward P/E of 18.14. For a more detailed relative valuation and DCF analysis to assess GE Healthcare Technologies Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
18.14
Current PE
14.49
Overvalued PE
19.97
Undervalued PE
16.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.42
Current EV/EBITDA
9.39
Overvalued EV/EBITDA
12.95
Undervalued EV/EBITDA
9.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.73
Current PS
1.47
Overvalued PS
1.98
Undervalued PS
1.47

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

je veux trader sur le nasdaq 100
Intellectia · 16 candidates
Price: $10.00 - $500.00Analyst Consensus: Strong Buy, Moderate BuyBeta: ModerateRiskIs Index Component: NDX
Ticker
Name
Market Cap$
top bottom
AAPL logo
AAPL
Apple Inc
3.76T
GOOG logo
GOOG
Alphabet Inc
3.70T
MSFT logo
MSFT
Microsoft Corp
2.98T
NFLX logo
NFLX
Netflix Inc
324.56B
ISRG logo
ISRG
Intuitive Surgical Inc
172.54B
PDD logo
PDD
PDD Holdings Inc
142.36B
NASDAQ100 stock with fairly or undervalue
Intellectia · 10 candidates
Analyst Consensus: Strong Buy, Moderate Buy, HoldPe Ttm: 8 - 22P/B Ratio: <= 4.00Is Index Component: NDXEv Ebitda: <= 15
Ticker
Name
Market Cap$
top bottom
FANG logo
FANG
Diamondback Energy Inc
44.13B
PDD logo
PDD
PDD Holdings Inc
152.56B
PYPL logo
PYPL
PayPal Holdings Inc
53.15B
BIIB logo
BIIB
Biogen Inc
25.32B
TMUS logo
TMUS
T-Mobile US Inc
211.11B
CTSH logo
CTSH
Cognizant Technology Solutions Corp
41.28B
how do i create a customized screener
Intellectia · 94 candidates
Market Cap: >= 5.00BMarket Cap Category: large, midNet Margin: >= 5.00Beta: ModerateRiskPe Ttm: 10 - 30Return On Equity: >= 10.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
PDD logo
PDD
PDD Holdings Inc
150.37B
BBVA logo
BBVA
Banco Bilbao Vizcaya Argentaria SA
141.76B
AEM logo
AEM
Agnico Eagle Mines Ltd
103.10B
BMO logo
BMO
Bank of Montreal
96.25B
PNC logo
PNC
PNC Financial Services Group Inc
91.17B
USB logo
USB
US Bancorp
86.26B
show me stocks that have beta =0.8 Alfa =+5
Intellectia · 25 candidates
Market Cap: 20.00B - 50.00BBeta: ModerateRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
DHI logo
DHI
D.R. Horton Inc
45.93B
DAL logo
DAL
Delta Air Lines Inc
45.02B
KGC logo
KGC
Kinross Gold Corp
43.05B
EL logo
EL
Estee Lauder Companies Inc
42.48B
JD logo
JD
JD.com Inc
41.25B
TCOM logo
TCOM
Trip.com Group Ltd
40.50B

Whales Holding GEHC

B
Barrow, Hanley, Mewhinney & Strauss, LLC
Holding
GEHC
+7.61%
3M Return
C
Castle Hook Partners LP
Holding
GEHC
+7.20%
3M Return
O
Omega Advisors, Inc.
Holding
GEHC
+7.17%
3M Return
S
Scout Investments, Inc.
Holding
GEHC
+7.16%
3M Return
H
Hotchkis and Wiley Capital Management, LLC
Holding
GEHC
+6.60%
3M Return
M
Menora Mivtachim Provident Funds
Holding
GEHC
+6.44%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is GE Healthcare Technologies Inc (GEHC) stock price today?

The current price of GEHC is 74.15 USD — it has decreased -0.68

What is GE Healthcare Technologies Inc (GEHC)'s business?

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.

What is the price predicton of GEHC Stock?

Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is92.25 USD with a low forecast of 80.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is GE Healthcare Technologies Inc (GEHC)'s revenue for the last quarter?

GE Healthcare Technologies Inc revenue for the last quarter amounts to 5.70B USD, increased 7.13

What is GE Healthcare Technologies Inc (GEHC)'s earnings per share (EPS) for the last quarter?

GE Healthcare Technologies Inc. EPS for the last quarter amounts to 1.29 USD, decreased -17.83

How many employees does GE Healthcare Technologies Inc (GEHC). have?

GE Healthcare Technologies Inc (GEHC) has 54000 emplpoyees as of April 21 2026.

What is GE Healthcare Technologies Inc (GEHC) market cap?

Today GEHC has the market capitalization of 33.83B USD.